$SNY (Sanofi) — investor discussion on X

Sanofi Q3 Beats, Raises 2026 Guidance

Q3 sales beat on Dupixent strength; FY26 sales and EPS outlook raised

Sanofi's CirCLIQ Injector Approved in Japan for Sarclisa Subcutaneous Use

enFuse-based injector approved to administer Sarclisa subcutaneous formulation in multiple myeloma patients

Sanofi Breaks Ground on New Insulin Manufacturing Facility in Frankfurt, Germany

Groundbreaking at BioCampus to expand insulin manufacturing capacity

Sanofi Exercises Option on Recursion's Potential First-in-Class Immunology Candidate

Oral dual-targeting small molecule to enter pipeline; Phase 1 planned for 2027

EU Accepts Sanofi's Concessions to Settle Antitrust Probe

Avoids fine but must rectify past marketing practices to address competition concerns

Sanofi and Regeneron Expand Immunology Alliance, Up to $8B

Sanofi pays $1B upfront and up to $7B milestones for 4 long-acting antibodies, boosting inflammation pipeline

Sanofi's MenQuadfi EU Approved for Infants from 6 Weeks

Expands indication to infants, strengthening meningococcal prevention and market position

Sanofi Beats Q2, Raises 2026 Guidance

Dupixent tops €5B quarterly sales; new CEO's first address focuses on pipeline revival

Earnings report

Sanofi's Amlitelimab Halt Spurs M&A Speculation

Market eyes Sanofi's €14-15B M&A budget for 2026, potential ABVX acquisition

Sanofi discontinues amlitelimab submission for atopic dermatitis globally

Market discusses Sanofi's cash position and potential acquisition of ABVX

Sanofi announces Executive Committee evolution to support next strategic chapter

Company restructures top leadership team to focus on business units and strategic execution

Sanofi Expands AI Drug Discovery Collaboration with Aqemia

Sanofi and Aqemia announced expansion of multi-year research collaboration in small molecule drug invention.